Glycosphingolipids for use in modulating immune responses
US10227290B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Feb 7, 2013 |
| Grant date | Mar 12, 2019 |
| Priority date | — |
| Expiry date | Nov 4, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2035/122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.